- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 08.12.25 | Dr. Reddy's pens $370M pact for rights to Immutep's phase 3-stage immunotherapy in certain markets | ||
| 08.12.25 | Dyne readies FDA push after DMD exon 51 med excels in trial | ||
| 08.12.25 | Wave, Structure stocks double on obesity data readouts | ||
| 08.12.25 | Mirum beckons Bluejay and its phase 3-stage hepatitis drug for $620M | ||
| 08.12.25 | China's Ascletis reports 7.7% weight loss for oral GLP-1 contender in US phase 2 study | ||
| 08.12.25 | BioNTech's CTLA-4 drug improves survival in phase 3 cancer trial but poses tolerability challenge | ||
| 08.12.25 | AbbVie hands back phase 1 duties for chronic inflammation drug to partner OSE | ||
| 07.12.25 | ASH: Anito-cel strengthens best-in-class potential as Gilead's Kite preps for launch | ||
| 05.12.25 | 'Unprecedented turmoil' engulfing FDA threatens public health: mRNA coalition speaks out | ||
| 05.12.25 | Encoded deciphers path to pivotal trial with phase 1/2 Dravet gene therapy data | ||
| 05.12.25 | 'Market's thinking is backwards': FDA's 1-trial approval plan would boost R&D spend, Jefferies says | ||
| 05.12.25 | Praxis claims efficacy success in phase 2 seizure trial, setting up approval talks with FDA | ||
| 05.12.25 | Pfizer Ventures gets behind Chinese biotech's $100M series A to boost R&D hub's capability | ||
| 04.12.25 | FDA slaps hold on Denali's plans for phase 1 rare disease trial | ||
| 04.12.25 | Royalty pens $275M financing deal for Denali drug awaiting delayed FDA decision | ||
| 04.12.25 | Crescent waxes pipeline with $80M Kelun deal, bagging ADC to pair with PD-1xVEGF bispecific | ||
| 04.12.25 | AstraZeneca's latest amyloidosis pact with Neurimmune could reach $780M | ||
| 04.12.25 | FDA names Tracy Beth Hoeeg, fresh from vaccine safety probe, as acting head of drug center | ||
| 03.12.25 | FDA floats user fee cuts for early-stage US trials, additional fees for overseas development | ||
| 03.12.25 | Capricor's phase 3 win sets up 2nd approval attempt for Duchenne cell therapy | ||
| 03.12.25 | Pfizer-backed Triana scores $120M series B to take molecular glue degrader into clinic | ||
| 03.12.25 | Pharvaris clocks a pivotal win in race for rapid HAE relief, teeing up filing to challenge KalVista | ||
| 03.12.25 | Théa pens $280M deal for Iolyx's phase 3-ready dry eye disease drug | ||
| 03.12.25 | Muvon flexes muscle cell therapy data to challenge synthetic incontinence implants | ||
| 02.12.25 | CDER head Richard Pazdur set to retire shortly after appointment: Stat |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.